Last updated: 2026-09-07 01:22:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Bio-Rad Laboratories, Inc. (BIO) operates in the LABORATORY ANALYTICAL INSTRUMENTS sector and is listed on NYSE. The stock is currently priced at $386.21, with a market capitalisation of $10.32B and a P/E ratio of 46.42. Over the past 52 weeks, its price has ranged from $236.73 to $396.23. This page covers its latest market performance, valuation, price trends and company information.
$10.32B | |
$376.49 | |
$832.70 | |
$46.54 | |
$387.90 | |
80.23K | |
298.38K | |
46.42 | |
$396.23 | |
$236.73 | |
-- | |
-- |
Bio-Rad Laboratories, Inc. (BIO) last closed at $387.90 as of 2026-09-05 00:00:00, unchanged from the previous close of $387.90.
During the latest regular trading session, BIO traded between $46.54 and $832.70, with a volume of 80.23K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Bio-Rad Laboratories, Inc. (BIO) moved from $389.94 to $386.21, representing a decline of 0.96% ($3.73).
The stock traded between $374.75 and $396.23 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 222.39 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 93.7%
BIO is currently trading at $386.21, placing it 93.7% of the way from its 52-week low of $236.73 to its 52-week high of $396.23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees | 7450 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Bio-Rad Laboratories, Inc. (BIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.